Objective: This study assessed the impact of a fixed-dose combination 5α-reductase inhibitor (5-ARI) dutasteride 0.5 mg and the α-blocker (AB) tamsulosin 0.4 mg on erectile dysfunction (ED) using The International Index of Erectile Function-5 (IIEF-5) score and Erectile Hard Score (EHS) in patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Material & Methods: This was an analytical cross-sectional with consecutive sampling. We reviewed the medical records of the symptomatic BPH patients. Then we interviewed The International Prostate Symptom Score (IPSS), Quality of Life (QOL), IIEF-5, and EHS scores after administered combination therapy. The data were analyzed with SPSS IBM 21.0 using univariate and then bivariate analysis. Results: Forty (40) patients fulfilled inclusion criteria. The results showed that the frequency of patients at most in the age range of 50-59 years (40%), most of IPSS after therapy showed mild grade 45%, and moderate grade 55%. The QOL average score is 2.08, most of the patients felt pleased (35%). IIEF-5 average score after treatment is 11.6 (moderate ED) and the EHS is 2.48 (grade 2: tumescence with minimal rigidity). The Spearman test showed that there was no correlation between IPSS and IIEF-5, the score is -0.658. Then, the Spearman correlation score between BPH grade after combination treatment and ED grade is 0.739 and had a statistically significant 0.000 (p<0.001). Conclusion: This research shows that there is a correlation of the impact of tamsulosin/ dutasteride combination therapy on ED in BPH with secondary LUTS. Keywords: BPH, erectile dysfunction, tamsulosin/dutasteride combination.
BPH, erectile dysfunction, tamsulosin/dutasteride combination
Tjahjodjati., Soebadi Doddy M., Umbas, Raini., Purnomo, Basuki Bambang., W. et al. Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic HHyperplasia/BPH) (3rd ed.). IAUI. 2017.
Parsons, JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010; 5: 212–218.
Egan, KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016; 43: 289–297.
Lokeshwar, Soum D., Benjamin T. Harper, Eric Webb, Andre Jordan, T. A. D. et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019; 8: 529–539.
De Nunzio C, Roehrborn CG, Andersson KE, et al. Erectile Dysfunction and Lower Urinary Tract Symptoms. Eur Urol Focus. 2017; 3: 352–363.
Rosen A Raymond, Claus G. Roehrborn, Michael J. Manyak, Juan Manuel Palacios-Moreno, T.H. et al. Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-contr. Int J Clin Pract. 2019; 73.
Umul, Mehmet, Ahmet Barış Altay, Fikret Bademkiran, B. T. et al. The relationship between lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: the role of autonomic hyperactivity. Turk J Med Sci. 2014; 44: 681–686.
Birowo, Ponco., Isaac Ardianson Deswanto, N. R. Epidemiology of erectile dysfunction: A cross-sectional webbased survey conducted in an Indonesian national referral hospital. F1000Research. 2021; 8: 817.
Rhoden EL, Telöken C, Sogari PR, et al. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002; 14: 245–250.
Tang Z, Li D, Zhang X, et al. Comparison of the simplified International Index of Erectile Function (IIEF-5) in patients of erectile dysfunction with different pathophysiologies. BMC Urol. 2014; 14: 52.
Zuhirman, Z. Success rates of tamsulosin and dutasteride as
medical therapy basen on IPSS in symptomatic BPH patients in arifin achmad hospital pekan baru riau. Indonesian Journal of Urology. 2018; 25: 110–114.
Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the combAT study. Eur Urol. 2010; 57: 123–131.
Becher, E., CG Roehrborn, P Siami, RP Gagnier, T. W. and F.M. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer and Prostatic Diseases. 2009; 12: 369–374.
Zhou, Zhongbao., Yuanshan Cui, Jitao Wu, Rui Ding, T. C. et al. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urology. 2019; 19.
Erdemir F, Harbin A, H. W. 5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection. J Sex Med. 2008; 5: 2917–2924.
Shigehara K, Miyagi T, Nakashima T, et al. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction. Aging Male. 2016; 19: 128–133.
Sahin Kilic, Engin Kolukcu, Fikret Erdemir, Ismail Benli, A. A. The Effects of Oral 5- alpha Reductase Inhibitors on Penile Intracavernosal Pressures and Penile Morphology in Rat Model. Sexual Dysfunction and Andrology. 2019; 16.
Song SH, Son H, Kim KT, Kim SW, Moon du G, Moon KH, et al. (2011). Effect of tamsulosin on Ejaculatory function in BPH/LUTS. Asian J Androl. 2011; 13: 846–850.
Stojanović Nebojša A., Ivan Ignjatović, Nebojša Djenić, D. B. Adverse Effects of Pharmacological Therapy of Benign Prostatic Hyperplasia on Sexual Function in Men. Srp Arh Celok Lek. 2015; 143: 284–289.
McVary, KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol. 2005; 47: 838–845.